Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oscient Pharmaceuticals Corp.

Latest From Oscient Pharmaceuticals Corp.

Appointments: Novo Nordisk, Horizon Pharma, Jounce Therapeutics, Pfenex and Pharmalink

This week's roundup includes CEO appointments by ProTA and Pfenex with various other high-level appointments by Novo Nordisk, Jounce Therapeutics and Pharmalink.

Appointments BioPharmaceutical

Lupin's US revenues could double by 2015 as products hit

Lupin, India's third largest drug firm by sales, reported a 38% jump in net sales to Rs24.65 billion ($463 million) for the third quarter ended 31 December 2012, buoyed by a strong showing in the US market. Net profits grew by 43% to Rs3.35 billion.


Generic Tricor could boost Lupin in the US but shadow on Antara

Lupin has introduced fenofibrate tablets 48mg and 145mg, generic versions of Abbott's TriCor, on the US market, in what’s seen as a ‘material’ launch for the Indian firm in the short term. The genericisation of Tricor, though, could also potentially dull the prospects of Lupin’s Antara (fenofibrate capsules 43mg and 130mg) brand there, some analysts said.

Stockwatch: New antibiotics: easy to say; hard to do

Most of the contemporary challenges for the western world are easy to identify, but difficult to resolve. These include the pensions time-bomb, the obesity epidemic, the patent cliff, the European sovereign debt crisis and the lack of new antibiotics. While the European sovereign debt crisis lurched into a significantly worse position this week, two other announcements proposed remedies to two of these challenges.

Metabolic Disorders Dermatology
See All

Company Information